Tags

Type your tag names separated by a space and hit enter

Prospective survey of patient-controlled epidural analgesia with bupivacaine and hydromorphone in 3736 postoperative orthopedic patients.
Reg Anesth Pain Med. 2010 Jul-Aug; 35(4):351-4.RA

Abstract

BACKGROUND AND OBJECTIVES

Patient-controlled epidural analgesia(PCEA) has been shown to be superior to intravenous patient-controlled analgesics (PCA) for postoperative analgesia after thoracic, abdominal, pelvic, and lower extremity surgery. However, it is unclear which opioid is optimal for PCEA. Hydromorphone has potential advantages, yet there are no data to establish its efficacy and safety. Thus, we prospectively monitored our patients receiving PCEA with bupivacaine combined with hydromorphone after orthopedic surgery.

METHODS

All postoperative patients who received PCEA from March 1 to September 21, 2009, were included. Lumbar PCEA was initiated after central neuraxial anesthesia with 0.06% bupivacaine combined with hydromorphone 10 microg/mL. Initial settings were a bolus dose of 4 mL, lockout interval of 10 mins, and background infusion of 4 mL/hr. Patients were allowed oral analgesics, and meloxicam was routinely administered as an adjunct analgesic. Patients were evaluated twice a day at our Acute Pain Service department. Pain scores, adverse effects, and medications were entered prospectively into the electronic patient record.

RESULTS

Verbal pain scores (0Y10) at rest were 3, 3, 3, and 2 on postoperative days 0 to 3. Verbal pain scores with activity were 4, 3, 3, and 3. Most adverse effects were modest to rare (15% pruritus, 10% hypotension,0.08% sedation, and 0% respiratory depression) with the exception of nausea (30%). There were no epidural hematomas or abscesses. Median duration of PCEA was 27 hrs.

CONCLUSIONS

Patient-controlled epidural analgesia with bupivacaine and hydromorphone provides effective and safe postoperative analgesia for orthopedic surgery.

Authors+Show Affiliations

Department of Anesthesiology, Hospital for Special Surgery, 535 E 70th St, New York, NY 10021, USA. liusp@hss.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20607876

Citation

Liu, Spencer S., et al. "Prospective Survey of Patient-controlled Epidural Analgesia With Bupivacaine and Hydromorphone in 3736 Postoperative Orthopedic Patients." Regional Anesthesia and Pain Medicine, vol. 35, no. 4, 2010, pp. 351-4.
Liu SS, Bieltz M, Wukovits B, et al. Prospective survey of patient-controlled epidural analgesia with bupivacaine and hydromorphone in 3736 postoperative orthopedic patients. Reg Anesth Pain Med. 2010;35(4):351-4.
Liu, S. S., Bieltz, M., Wukovits, B., & John, R. S. (2010). Prospective survey of patient-controlled epidural analgesia with bupivacaine and hydromorphone in 3736 postoperative orthopedic patients. Regional Anesthesia and Pain Medicine, 35(4), 351-4.
Liu SS, et al. Prospective Survey of Patient-controlled Epidural Analgesia With Bupivacaine and Hydromorphone in 3736 Postoperative Orthopedic Patients. Reg Anesth Pain Med. 2010 Jul-Aug;35(4):351-4. PubMed PMID: 20607876.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prospective survey of patient-controlled epidural analgesia with bupivacaine and hydromorphone in 3736 postoperative orthopedic patients. AU - Liu,Spencer S, AU - Bieltz,Mihai, AU - Wukovits,Barbara, AU - John,Raymond S, PY - 2010/7/9/entrez PY - 2010/7/9/pubmed PY - 2010/10/19/medline SP - 351 EP - 4 JF - Regional anesthesia and pain medicine JO - Reg Anesth Pain Med VL - 35 IS - 4 N2 - BACKGROUND AND OBJECTIVES: Patient-controlled epidural analgesia(PCEA) has been shown to be superior to intravenous patient-controlled analgesics (PCA) for postoperative analgesia after thoracic, abdominal, pelvic, and lower extremity surgery. However, it is unclear which opioid is optimal for PCEA. Hydromorphone has potential advantages, yet there are no data to establish its efficacy and safety. Thus, we prospectively monitored our patients receiving PCEA with bupivacaine combined with hydromorphone after orthopedic surgery. METHODS: All postoperative patients who received PCEA from March 1 to September 21, 2009, were included. Lumbar PCEA was initiated after central neuraxial anesthesia with 0.06% bupivacaine combined with hydromorphone 10 microg/mL. Initial settings were a bolus dose of 4 mL, lockout interval of 10 mins, and background infusion of 4 mL/hr. Patients were allowed oral analgesics, and meloxicam was routinely administered as an adjunct analgesic. Patients were evaluated twice a day at our Acute Pain Service department. Pain scores, adverse effects, and medications were entered prospectively into the electronic patient record. RESULTS: Verbal pain scores (0Y10) at rest were 3, 3, 3, and 2 on postoperative days 0 to 3. Verbal pain scores with activity were 4, 3, 3, and 3. Most adverse effects were modest to rare (15% pruritus, 10% hypotension,0.08% sedation, and 0% respiratory depression) with the exception of nausea (30%). There were no epidural hematomas or abscesses. Median duration of PCEA was 27 hrs. CONCLUSIONS: Patient-controlled epidural analgesia with bupivacaine and hydromorphone provides effective and safe postoperative analgesia for orthopedic surgery. SN - 1532-8651 UR - https://www.unboundmedicine.com/medline/citation/20607876/Prospective_survey_of_patient_controlled_epidural_analgesia_with_bupivacaine_and_hydromorphone_in_3736_postoperative_orthopedic_patients_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=20607876.ui DB - PRIME DP - Unbound Medicine ER -